A retrospective cohort study in the Netherlands evaluated the real-world effectiveness of the biosimilar adalimumab Hyrimoz ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

The frequency of blinking can affect the stability of tear film in those living with dry eye, with the threshold of 20 blinks ...

Peter Voorhees, MD, explains how daratumumab and hyaluronidase-fihj show superior efficacy in delaying progression of MM ...

The study, “The Role of Utilizing Community Oncology Care To Decrease Cancer-Related Financial Toxicity,” 1 analyzes ...

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says ...

Guideline-recommended therapies for heart failure (HF) were found to be ineffective in patients with HF caused by Chagas ...

Reduced costly care: Behavioral health–related emergency department visits and inpatient admissions decreased by 35% and 43%, respectively. Lower total medical costs: The intervention group saved ...

Adults with type 1 diabetes (T1D) and type 2 diabetes (T2D) face substantially higher rates of sudden cardiac death (SCD) across all age groups, especially younger adults, according to findings from a ...

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...